Nakom Mite (Levodopa, Carbidopa Monohydrate)

Levodopa/Carbidopa, the active ingredient in Nakom Mite, is a Levodopa/Carbidopa combination presented as an oral tablet for oral use. It works by restoring dopamine levels in the brain and is indicated for the treatment of Parkinson's disease motor symptoms in adult patients.

GNH USA supplies Nakom Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global healthcare providers.

Nakom Mite (levodopa/carbidopa) is used in the dopaminergic pathway to treat Parkinson's disease and related disorders.

- Parkinson's disease: improves motor function, reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates motor symptoms in secondary Parkinsonism. - Levodopa‑responsive dystonia: decreases abnormal muscle contractions in patients responsive to levodopa.

Nakom Mite may cause a range of adverse reactions. Patients should be informed of common and serious possibilities.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or other psychiatric disturbances - Severe hypotension or arrhythmias - Neuroleptic malignant syndrome (very rare) - Allergic skin reactions such as rash or urticaria

Before initiating therapy, clinicians should consider several safety measures.

- Dose titration: start low and increase gradually to minimize adverse effects. - Monitor blood pressure: risk of orthostatic hypotension, especially in the elderly. - Assess renal and hepatic function: adjust dosing if impairment is present. - Avoid abrupt discontinuation: sudden stop may worsen Parkinsonian symptoms. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Levodopa/carbidopa can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may diminish therapeutic efficacy. - High‑protein meals: can reduce levodopa absorption.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may increase risk of serotonin syndrome. - Diuretics: can exacerbate orthostatic hypotension. - Antihypertensive drugs: additive blood‑pressure‑lowering effect.